Pfizer's Obesity Drug Breakthrough: A Weighty Market Move

Pfizer's experimental obesity drug, acquired through Metsera, shows promise, reporting up to 12.3% weight loss in a 28-week trial. Targeting regulatory approval by 2028, Pfizer plans over 20 clinical trials, eyeing the potential $150 billion market. Despite patent expirations, the company aims to boost growth with innovative treatments.

Pfizer announced on Tuesday that an experimental obesity drug, obtained via its $10 billion acquisition of Metsera, has demonstrated substantial weight loss after 28 weeks of treatment as a monthly injection.

The pharmaceutical giant is planning to seek regulatory approval by 2028 for what could be a lucrative addition to the rapidly expanding weight-loss medication market.

This move is seen as part of Pfizer's strategy to counter challenges, including patent expirations, by investing in blockbuster drugs.

(With inputs from agencies.)